Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01801046 · ClinicalTrials.gov registry record · Phase 1
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
A Phase 1 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01801046 is a Phase 1 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 10 participants.
The verdict
NCT01801046, a Phase 1 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects of donor stem cell transplant in treating patients with high risk acute myeloid leukemia. Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect)
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE peripheral blood stem cell transplantation
- DRUG cytarabine
- DRUG mitoxantrone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-03-06 |
| Est. Completion | 2017-08-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01801046
The ClinicalTrials.gov registry entry for NCT01801046 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01801046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01801046 about?
NCT01801046 is a clinical study titled "Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia". This phase I trial studies the side effects of donor stem cell transplant in treating patients with high risk acute myeloid leukemia. Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune sys...
What is the current status of trial NCT01801046?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2013-03-06. Estimated completion is 2017-08-20.
What interventions are being tested in trial NCT01801046?
The interventions under investigation include: laboratory biomarker analysis (OTHER), peripheral blood stem cell transplantation (PROCEDURE), cytarabine (DRUG), mitoxantrone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01801046?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.